ASVRX
Price
$11.32
Change
+$0.58 (+5.40%)
Updated
Nov 7 closing price
ESPIX
Price
$46.87
Change
-$0.56 (-1.18%)
Updated
Nov 7 closing price
Ad is loading...

ASVRX vs ESPIX

Header iconASVRX vs ESPIX Comparison
Open Charts ASVRX vs ESPIXBanner chart's image
American Century Small Cap Value R
Price$11.32
Change+$0.58 (+5.40%)
VolumeN/A
CapitalizationN/A
Allspring Special Small Cap Value Adm
Price$46.87
Change-$0.56 (-1.18%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
ASVRX vs ESPIX Comparison Chart
Loading...
VS
ASVRX vs. ESPIX commentary
Nov 08, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ASVRX is a Buy and ESPIX is a Buy.

FUNDAMENTALS
Fundamentals
ESPIX pays higher dividends than ASVRX: ESPIX (0.87) vs ASVRX (0.47). ASVRX was incepted earlier than ESPIX: ASVRX (15 years) vs ESPIX (28 years). ASVRX is a more actively managed with annual turnover of: 44.00 vs. ESPIX (22.00). ASVRX has a lower initial minimum investment than ESPIX: ASVRX (2500) vs ESPIX (1000000). ASVRX annual gain was more profitable for investors over the last year : 32.64 vs. ESPIX (29.17). ASVRX return over 5 years is better than : 49.49 vs. ESPIX (34.95).
ASVRXESPIXASVRX / ESPIX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence15 years28 years-
Gain YTD12.26713.45991%
Front LoadN/AN/A-
Min. Initial Investment250010000000%
Min. Initial Investment IRAN/AN/A-
Net Assets5.95BN/A-
Annual Yield % from dividends0.470.8754%
Returns for 1 year32.6429.17112%
Returns for 3 years-2.03-0.141,437%
Returns for 5 years49.4934.95142%
Returns for 10 years18.7347.0240%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BNOX0.380.10
+36.25%
Bionomics Limited
NNDM2.200.02
+0.92%
Nano Dimension Ltd
SNN24.700.22
+0.90%
Smith & Nephew plc
ODD42.11-1.33
-3.06%
ODDITY Tech Ltd
AVTX12.91-0.49
-3.66%
Avalo Therapeutics